clinical trial · NCT02918968
Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate Cancer
Prostate CancerEnzalutamideFlutamideAndrogen deprivation therapy
brief summary
The objective of this study was to compare the efficacy and safety of the combination therapy with enzalutamide + androgen deprivation therapy (ADT) and the combination therapy with flutamide + ADT in patients with castration resistant prostate cancer who had relapsed during combined androgen blockade (CAB) therapy with bicalutamide and ADT. This study also investigated the order of alternative antiandrogen therapy (AAT) by changing the 1st line medication after relapse of prostate-specific antigen (PSA).
started
Nov 2, 2016
primary completion
Mar 27, 2020
completion
Mar 27, 2020
last updated
Dec 9, 2024
official title
A Randomized Phase IV Study Comparing Enzalutamide Versus Flutamide in Castration-resistant Prostate Cancer (CRPC) Patients Who Have Failed Combined Androgen Blockade Therapy With Bicalutamide Plus Androgen Deprivation Therapy (ADT)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol